The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

UBS Group: The price reduction of the tenth round of collective procurement of Pharmaceuticals exceeded expectations, showing a cautious attitude towards the China generic drug market.

UBS Group released a research report stating that the tenth batch of national Pharmaceutical procurement in the mainland involves 62 types of Pharmaceuticals, with 385 products eligible for selection. Although the government has not disclosed the price reduction situation, according to Statistics, this time the reduction exceeds expectations, reaching 80% to 96%, and it is believed to be the largest reduction in history. The results of the Pharmaceutical procurement will be comprehensively implemented nationwide starting from April next year and will remain effective until the end of 2027. Overall, UBS Group believes that the results of the tenth batch of national Pharmaceutical procurement reflect China's tightening of the basic Medical Insurance Fund, and the government has also increased support for new drugs. Looking ahead, the bank holds a cautious attitude towards the prospects of China's generic drug market, and also anticipates.

AASTOCKSDec 19 09:49

Zhongtai International: Initially assigns a "Buy" rating to LUYE PHARMA (02186) with a Target Price of 2.9 Hong Kong dollars.

Zhongtai International expects LUYE PHARMA's revenue CAGR from 2023 to 2026 to be 7.2%.

Zhitong FinanceDec 19 09:17

Luye Pharma Chairman Increases Stake, Signals Confidence

TipRanksDec 18 20:40

LUYE PHARMA (02186.HK) has seen its Executive Chairman Liu Dianbo increase his shareholding by a total of 2 million shares.

On December 18, Gelonghui reported that LUYE PHARMA (02186.HK) announced that the company's Board of Directors received notification from Mr. Liu Dianbo, the company's executive director and executive chairman, that on December 18, 2024, through his controlled entity LUYE PHARMA Investment Limited, he purchased a total of 2 million shares of the company in the market, with an average purchase price of approximately HKD 2.2299 per share. Following the purchase and as of the date of this announcement, Mr. Liu has interests in 1,261,196,703 shares, accounting for approximately 33.53% of the company's total issued share capital. As Mr. Liu has informed, he remains optimistic about the company's growth, development, and future prospects.

Gelonghui FinanceDec 18 20:34

Zhongtai International Starts Luye Pharma Group at Buy With HK$2.90 Price Target

MT NewswiresDec 18 17:01 · Ratings